Generic lamotrigine extended‐release tablets are bioequivalent to innovator drug in fully replicated crossover bioequivalence study

Autor: Lanyan Fang, Zhichuan Li, Minori Kinjo, Sara Lomonaco, Nan Zheng, Wenlei Jiang, Liang Zhao
Rok vydání: 2022
Předmět:
Zdroj: Epilepsia. 64:152-161
ISSN: 1528-1167
0013-9580
Popis: Lamotrigine is a commonly prescribed antiepileptic drug. U.S. Food and Drug Administration (FDA)-funded clinical studies have demonstrated bioequivalence (BE) for generic lamotrigine immediate-release (IR) products in epilepsy patients with generic substitution. To address the potential concerns about the risk of generic-brand substitution of lamotrigine extended-release (ER) products, considering the complexity of controlled release systems and pharmacokinetic variations associated with possible within-subject variability (WSV), this prospective study assessed (1) BE of generic and brand lamotrigine ER products in a fully replicated BE study design in healthy subjects and (2) whether such fully replicated study design and WSV data can better support the approval of generic lamotrigine ER products.This open-label, single-dose, two-treatment, four-period, two-sequence, fully replicated crossover BE study compared generic lamotrigine ER tablet to brand Lamictal XR (200 mg) in 30 healthy subjects under fed conditions. Pharmacokinetics (PK) profiles were generated based on intensive blood sampling up to 144 h.The two products showed comparable peak plasma concentration (CThe generic lamotrigine ER tablet product demonstrates BE to the brand product in a fully replicated BE study design with healthy subjects, supporting the adequacy of the two-way crossover study design to demonstrate BE and generic-brand substitution of lamotrigine ER products.
Databáze: OpenAIRE
Externí odkaz: